Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
19 Setembro 2023 - 5:05PM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, today announced that
Company management will participate in a fireside chat at the 2023
Cantor Fitzgerald Global Healthcare Conference in New York on
Tuesday, September 26, 2023 at 11:40 a.m. ET / 8:40 a.m. PT.
A live webcast of the fireside chat can be accessed through the
Investors & Media section of the Company’s website at
http://investors.vaxcyte.com. A replay of the webcast will be
available for approximately 30 days following the conference.
About Vaxcyte Vaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing
pneumococcal conjugate vaccine (PCV) being developed for the
prevention of invasive pneumococcal disease. Vaxcyte is
re-engineering the way highly complex vaccines are made through
modern synthetic techniques, including advanced chemistry and the
XpressCF™ cell-free protein synthesis platform, exclusively
licensed from Sutro Biopharma, Inc. Unlike conventional cell-based
approaches, the Company’s system for producing difficult-to-make
proteins and antigens is intended to accelerate its ability to
efficiently create and deliver high-fidelity vaccines with enhanced
immunological benefits. Vaxcyte’s pipeline also includes VAX-31, a
31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate
designed to prevent Group A Strep infections; VAX-PG, a therapeutic
vaccine candidate designed to slow or stop the progression of
periodontal disease; and VAX-GI, a vaccine program designed to
prevent Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked. For more information, visit
www.vaxcyte.com.
Contacts:Jennifer Zibuda, Senior Director,
Investor RelationsVaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Janet Graesser, Vice President, Corporate Communications and
Investor Relations Vaxcyte, Inc.917-685-8799media@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Vaxcyte (NASDAQ:PCVX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024